Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...

Jyong Biotech Ltd., a Taiwan-based biotechnology company, recently completed its IPO on Nasdaq and participated in the BIO 2025 International Convention in Boston, where it showcased its flagship ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...